Work

Pharmacokinetics and Pharmacodynamics of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-δ,γ, Following Single- and Multiple-Dose Administration in Healthy Subjects and Patients with Advanced Hematologic Malignancies

Year: 2012

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v120.21.4853.4853

Authors: Joi Dunbar, Jylle Nevejans, Charlotte McKee, Kerrie Faia, Jan Jaap van Lier, Peter Pruim, Janet Stegehuis, Sue Zhao, Brad S. Kahl, Steven M. Horwitz, Manish Patel, Anas Younes, Ian W. Flinn

Institutions: Infinity Pharmaceuticals (United States), University of Wisconsin–Madison, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Sarah Cannon

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2562606704

FWCI: 0.385

Cites:

Cited by: 6

Related to: 10